Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA Negotiations: Early Communications, Breakthrough Still On Docket

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.


Related Content

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says
Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says
PDUFA Negotiations End With Differences To Resolve In Commitment Letter
PDUFA VI: Breakthrough Issues Among FDA Priorities
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
Califf Supports Combo Products Pathway At Confirmation Hearing
Breakthrough Requests: FDA Adds Quick Screen To Pare Workload
Investors Like “Breakthrough” Therapies, But Real Test Still To Come





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts